

Our ref: FOI 1062

27<sup>th</sup> May 2022

### FOI Response 1062

Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia]
- Adalimumab [Humira]
- Adalimumab Biosimilars
- Apremilast [Otezla]
- Baricitinib [Olumiant]
- Certolizumab [Cimzia]
- Etanercept [Enbrel]
- Etanercept Biosimilars
- Filgotinib [Jyseleca]
- Golimumab [Simponi]

• <b>Abatacept [Orencia]</b>	<b>72</b>
• <b>Adalimumab [Humira]</b>	<b>44</b>
• <b>Adalimumab Biosimilars</b>	<b>407</b>
• <b>Apremilast [Otezla]</b>	<b>0</b>
• <b>Baricitinib [Olumiant]</b>	<b>55</b>
• <b>Certolizumab [Cimzia]</b>	<b>64</b>
• <b>Etanercept [Enbrel]</b>	<b>22</b>
• <b>Etanercept Biosimilars</b>	<b>166</b>
• <b>Filgotinib [Jyseleca]</b>	<b>&lt;5</b>
• <b>Golimumab [Simponi]</b>	<b>84</b>

#### Part 2

- Guselkumab [Tremfya]
- Infliximab [Remicade]
- Infliximab Biosimilars
- Ixekizumab [Taltz]
- Risankizumab [Skyrizi]
- Rituximab [MabThera]
- Rituximab Biosimilars
- Sarilumab [Kevzara]
- Secukinumab [Cosentyx]
- Tocilizumab [Ro Actemra]
- Tofacitinib [Xeljanz]

- Upadacitinib [Rinvoq]
- Ustekinumab [Stelara]

• <b>Guselkumab [Tremfya]</b>	<b>0</b>
• <b>Infliximab [Remicade]</b>	<b>&lt;5</b>
• <b>Infliximab Biosimilars</b>	<b>30</b>
• <b>Ixekizumab [Taltz]</b>	<b>15</b>
• <b>Risankizumab [Skyrizi]</b>	<b>0</b>
• <b>Rituximab [MabThera]</b>	<b>0</b>
• <b>Rituximab Biosimilars</b>	<b>104</b>
• <b>Sarilumab [Kevzara]</b>	<b>6</b>
• <b>Secukinumab [Cosentyx]</b>	<b>107</b>
• <b>Tocilizumab [Ro Actemra]</b>	<b>42</b>
• <b>Tofacitinib [Xeljanz]</b>	<b>20</b>
• <b>Upadacitinib [Rinvoq]</b>	<b>10</b>
• <b>Ustekinumab [Stelara]</b>	<b>0</b>

Q2. Could you please provide the numbers of patients treated for Axial Spondyloarthritis ONLY in the last 3 months with the following drugs:

- Adalimumab [Humira]
- Adalimumab Biosimilars
- Certolizumab [Cimzia]
- Etanercept [Enbrel]
- Etanercept Biosimilars

• <b>Adalimumab [Humira]</b>	<b>&lt;5</b>
• <b>Adalimumab Biosimilars</b>	<b>17</b>
• <b>Certolizumab [Cimzia]</b>	<b>12</b>
• <b>Etanercept [Enbrel]</b>	<b>0</b>
• <b>Etanercept Biosimilars</b>	<b>&lt;5</b>

Part 3

- Golimumab [Simponi]
- Infliximab [Remicade]
- Infliximab Biosimilars
- Ixekizumab [Taltz]
- Secukinumab [Cosentyx]
- Upadacitinib [Rinvoq]

• <b>Golimumab [Simponi]</b>	<b>5</b>
• <b>Infliximab [Remicade]</b>	<b>0</b>
• <b>Infliximab Biosimilars</b>	<b>&lt;5</b>
• <b>Ixekizumab [Taltz]</b>	<b>&lt;5</b>
• <b>Secukinumab [Cosentyx]</b>	<b>0</b>
• <b>Upadacitinib [Rinvoq]</b>	<b>0</b>



The Trust has a legal duty to protect patient confidentiality and, in line with this duty, the figure <5 has been provided where figures are very low. This is because of the potential risk of identification of an individual. In reaching this decision the Trust has taken into account the small geographical area which the Trust serves and the sensitivity of the information requested. In addition the Trust has taken into account the fact that all information disclosed in response to an FOI is disclosed to the 'world at large' and is published on the Trust website.

S 40 (2) (third party information) of the Freedom of Information Act 2000 has been applied to exempt the redacted information from disclosure. The Trust does not consider the disclosure of the redacted information to be fair to the individuals concerned as there is the potential risk of identification of an individual(s) which they would not expect, and which would therefore breach the fairness element of the first principle of the Data Protection Act 2018.

Contact: [FOI.team@southerntrust.hscni.net](mailto:FOI.team@southerntrust.hscni.net)